DI TOMMASO, VALERIA
 Distribuzione geografica
Continente #
NA - Nord America 990
EU - Europa 829
AS - Asia 446
Continente sconosciuto - Info sul continente non disponibili 4
Totale 2.269
Nazione #
US - Stati Uniti d'America 990
CN - Cina 279
UA - Ucraina 171
IE - Irlanda 164
TR - Turchia 123
GB - Regno Unito 111
SE - Svezia 100
IT - Italia 88
FR - Francia 74
DE - Germania 73
FI - Finlandia 41
IN - India 35
EU - Europa 4
IR - Iran 4
KR - Corea 3
BE - Belgio 2
GR - Grecia 2
CZ - Repubblica Ceca 1
DK - Danimarca 1
IL - Israele 1
PH - Filippine 1
RU - Federazione Russa 1
Totale 2.269
Città #
Jacksonville 234
Chandler 205
Dublin 164
Southend 106
Nanjing 83
Princeton 80
Ashburn 74
Beijing 65
Izmir 64
New York 42
Cambridge 39
Dearborn 37
Nanchang 28
Altamura 27
Wilmington 25
Shenyang 16
Norwalk 15
Washington 14
Grevenbroich 12
Ann Arbor 11
Tianjin 11
Jinan 10
Kunming 10
Torino 8
Hebei 7
Jiaxing 7
Lanzhou 7
Los Angeles 7
Campobasso 6
Chieti 6
Falls Church 6
Hangzhou 6
Leawood 6
Boardman 5
Changsha 5
Guangzhou 5
Monmouth Junction 5
Ardabil 4
Bologna 4
Changchun 4
San Mateo 4
Augusta 3
Borgomanero 3
Helsinki 3
Ningbo 3
San Vito Chietino 3
Taizhou 3
Teramo 3
Woodbridge 3
Zhengzhou 3
Brussels 2
Hanover 2
Mumbai 2
Orange 2
Palermo 2
Palo Alto 2
Shanghai 2
Tappahannock 2
Aachen 1
Andover 1
Ascoli Piceno 1
Centrale 1
Chengdu 1
Domusnovas 1
Duncan 1
Hyderabad 1
Manila 1
Meitingen 1
Monte di Procida 1
Montesilvano 1
Moscow 1
Mountain View 1
Nürnberg 1
Olomouc 1
Phoenix 1
Quanzhou 1
Redmond 1
Rome 1
San Salvo 1
Stanford 1
Walnut 1
Totale 1.540
Nome #
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 83
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 82
Increasing age at disability milestones among MS patients in the MSBase Registry 76
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 75
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 74
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 71
Nail loss after teriflunomide treatment: a new potential adverse event 68
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 67
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 66
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 66
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 65
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 64
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 64
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 63
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 62
JCV-Ab serostatus in MS patients treated with Natalizumab 62
Natalizumab-associated PML-IRIS: the Chieti experience. 62
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 62
Atypical presentation of Cadasil a diagnostic challenge 61
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 60
Epidural analgesia and caesarean delivery are not associated with post-partum relapses and disability in MS. 60
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 59
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 56
Tumor necrosis factor α blockade therapy in a case of resistant primary angiitis of the central nervous system 54
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 54
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 54
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study 53
Intramedullary Spinal Cord Glioblastoma: An Uncommon Diagnosis 53
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 53
Epidural analgesia and caesarean delivery are not associated with post-partum relapses and disability in MS 53
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 52
Increased risk of disability progression after pregnancy in MS patients with active disease 50
Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis 43
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 41
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 41
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 41
Pregnancy and fetal outcomes after Glatiramer acetate exposure in patients with Multiple Sclerosis 41
Stratify-2 Test in the clinical practice: results from a large multicentric italian database 41
Predictors of post-partum relapses and disability progression in Multiple Sclerosis 33
Totale 2.285
Categoria #
all - tutte 7.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.723


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201992 0 0 0 0 0 0 0 0 0 0 1 91
2019/2020512 157 39 4 0 41 33 62 52 9 43 71 1
2020/2021185 38 2 40 0 1 42 0 0 18 11 30 3
2021/2022153 0 3 6 29 6 5 11 13 8 5 24 43
2022/2023512 40 88 26 38 67 104 32 26 61 8 13 9
2023/2024296 15 21 24 11 30 144 40 0 1 7 3 0
Totale 2.285